Chai Discovery, a biotech startup leveraging artificial intelligence for drug discovery, has announced a successful close of its Series B funding round, securing $130 million. This latest investment propels the OpenAI-backed company to a valuation of $1.3 billion, underscoring growing confidence in AI's potential to revolutionize pharmaceutical development. The announcement was made on Monday, as detailed in a press release.
The Series B round was co-led by prominent venture capital firms General Catalyst and Oak HC/FT. Additional significant participation came from existing investors including Menlo Ventures, OpenAI, Dimension, Thrive Capital, Neo, Yosemite venture fund, Lachy Groom, and SV Angel. New investors Glade Brook and Emerson Collective also joined the round. With this latest injection of capital, Chai Discovery's total funding now exceeds $225 million.
Advancing AI for Molecular Discovery
Chai Discovery operates at the forefront of a rapidly expanding industry that views AI as a critical accelerator for drug development, a trend highlighted in recent scientific publications such as Nature. The company is dedicated to building advanced foundation models specifically tuned for drug discovery. Its core mission involves predicting intricate interactions between biochemical molecules, with the ultimate goal of reprogramming them to create novel cures. Notably, Menlo Ventures had previously led Chai's $70 million Series A round in August, signaling early investor confidence.
Last year, Chai Discovery introduced its first AI model, Chai 1, and has since launched its latest iteration, Chai 2. The company reports that Chai 2 achieves substantial improvements in success rates compared to conventional methods, particularly in de novo antibody design. This capability allows for the creation of custom antibodies from scratch, rather than merely modifying existing ones, opening new avenues for therapeutic innovation. More details on their models can be found on the Chai Discovery website.
"Our latest models can design molecules that have properties we'd want from actual drugs, and tackle challenging targets that have been out of reach," stated Josh Meier, Chai Discovery's co-founder and CEO.
Meier, whose background is rooted in machine learning, previously held research and engineering roles at Facebook and, prior to that, worked at OpenAI. His professional history is publicly available on his LinkedIn profile. His expertise aligns directly with Chai Discovery's ambition to create a "computer-aided design suite" for molecules, fundamentally transforming how new medicines are conceived and developed.
